0000000001226784

AUTHOR

S Puzelli

showing 3 related works from this author

Transmission of hemagglutinin D222G mutant strain of pandemic (H1N1) 2009 virus.

2010

A pandemic (H1N1) 2009 virus strain carrying the D222G mutation was identified in a severely ill man and was transmitted to a household contact. Only mild illness developed in the contact, despite his obesity and diabetes. The isolated virus reacted fully with an antiserum against the pandemic vaccine strain.

MaleEpidemiologyvirusesMutantResistancelcsh:MedicineHemagglutinin Glycoproteins Influenza VirusSettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeSeverity of Illness IndexDisease Outbreakschemistry.chemical_compoundInfluenza A Virus H1N1 SubtypePandemicInfluenza A virusA/H1N1PhylogenyTransmission (medicine)H1N1DispatchtransmissionMiddle AgedInfectious DiseasesD222GItalyInfluenza A virusRNA ViralinfluenzaMicrobiology (medical)AdultOseltamivirMutation MissenseHemagglutinin (influenza)BiologyViruslcsh:Infectious and parasitic diseasesMicrobiologyOseltamivirInfluenza HumanmedicineHumanslcsh:RC109-216virusesRetrospective StudiesAntiserumSequence Analysis RNApandemiclcsh:RMutantVirologyInfluenzaH1N1 subtypechemistryAmino Acid Substitutionbiology.proteinA/H1N1vmutationInfluenza; A/H1N1v; Oseltamivir; ResistanceEmerging infectious diseases
researchProduct

Molecular surveillance of pandemic influenza A(H1N1) viruses circulating in Italy from May 2009 to February 2010: association between haemagglutinin …

2010

Haemagglutinin sequences of pandemic influenza A(H1N1) viruses circulating in Italy were examined, focusing on amino acid changes at position 222 because of its suggested pathogenic relevance. Among 169 patients, the D222G substitution was detected in three of 52 (5.8%) severe cases and in one of 117 (0.9%) mild cases, whereas the D222E mutation was more frequent and evenly distributed in mild (31.6%) and severe cases (38.4%). A cluster of D222E viruses among school children confirms reported human-to-human transmission of viruses mutated at amino acid position 222.

MaleMolecular surveillance; Pandemic influenza A(H1N1); Haemagglutinin mutations; Italy from May 2009 to February 2010pandemic influenzasurveillance of pandemic influenza A(H1N1); Molecular surveillance; pandemic influenzaEpidemiologyvirusesHaemagglutinin mutationssurveillance of pandemic influenza A(H1N1)Settore MED/42 - Igiene Generale E Applicatamedicine.disease_causeSeverity of Illness IndexInfluenza A Virus H1N1 SubtypePandemic influenza A(H1N1)PandemicInfluenza A VirusA(H1N1)ChildMutationReverse Transcriptase Polymerase Chain ReactionTransmission (medicine)Adolescent; Adult; Age Distribution; Aged; Amino Acid Substitution; Child; Child Preschool; Female; Hemagglutinins; Humans; Infant; Influenza A Virus H1N1 Subtype; Influenza Human; Italy; Male; Middle Aged; Mutation; Population Surveillance; Reverse Transcriptase Polymerase Chain Reaction; Severity of Illness Index; Sex Distribution; Young Adult; PandemicsMiddle AgedItaly from May 2009 to February 2010Molecular surveillance; pandemic influenza; A(H1N1); Italy; haemagglutinin mutationsHemagglutininsMolecular surveillanceItalyChild PreschoolPopulation SurveillanceFemaleHumanAdultAdolescentBiologyDisease clusterDisease courseYoung AdultAge DistributionVirologyInfluenza HumanmedicineHumansH1N1 SubtypeSex DistributionPreschoolhaemagglutinin mutationsPandemicsAgedMolecular epidemiologyPublic Health Environmental and Occupational HealthPandemic influenzaInfantVirologyInfluenzaMutational analysisAmino Acid SubstitutionMutationEurosurveillance
researchProduct

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

2018

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates. Funding: The five studies have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446 to conduct the study in…

0301 basic medicineMalePediatricsEpidemiologyvirusesInfluenza B viruinfluenza ; influenza vaccine effectiveness ; influenza vaccination ; case control study ; multicentre study ; EuropeEurope case control study influenza influenza vaccination influenza vaccine effectiveness multicentre study0302 clinical medicineInfluenza A Virus H1N1 Subtype[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInteriminfluenza vaccine effectivenessEpidemiologyPandemicInfluenza A Virus030212 general & internal medicineQAInfluenza vaccine effectivenessChildmedia_commonVaccine EffectivenessVaccinationvirus diseasesMiddle Agedinfluenza vaccinationmulticentre study3. Good healthVaccinationEuropeTreatment OutcomeInfluenza VaccinesChild PreschoolH3N2 SubtypeFemaleSeasonsInfluenza VaccineinfluenzaRapid CommunicationHumanAdultRMmedicine.medical_specialtyAdolescentInfluenza vaccine030106 microbiologyCase control studyMulticentre studyEuropean studiesSettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA03 medical and health sciencesVirologyInfluenza Humanmedicinemedia_common.cataloged_instanceHumansH1N1 SubtypeVacina AntigripalEuropean UnionEuropean unionPreschoolPandemicsAgedPandemicInfluenza A Virus H3N2 SubtypeCuidados de SaúdePublic Health Environmental and Occupational HealthInfant NewbornInfantInfluenza ainfluenza vaccine effectivenecase control studyNewbornEurope; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre studyInfluenzarespiratory tract diseasesInfluenza vaccinationInfluenza B virusEurope; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre study; Adolescent; Adult; Aged; Child; Child Preschool; Europe; European Union; Female; Humans; Infant; Infant Newborn; Influenza A Virus H1N1 Subtype; Influenza A Virus H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza Human; Male; Middle Aged; Pandemics; Treatment Outcome; Vaccination; Seasons[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieDeterminantes da Saúde e da Doença[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
researchProduct